Business
Enzolytics Announces the Discovery of Conserved Target Sites on the Monkeypox Virus
Enzolytics Announces the Discovery of Conserved Target Sites on the Monkeypox Virus.
About this update from Enzolytics Inc.
[{"type":"text","content":"COLLEGE STATION, TX / ACCESSWIRE / June 21, 2022 / Enzolytics, Inc. (OTC PINK:ENZC) (ENZC" or the "Company") today announced it has identified conserved, immutable sites (epitopes) on the Monkeypox virus. These discoveries are a part of Enzolytics' continuing efforts to address future healthcare needs in pandemics using its Comprehensive Artificial Intelligence (AI) protocol for producing Monoclonal Antibodies, including implementing AI analysis of existing viruses and any new virus immediately upon its emergence globally.The Chief Operating Officer, Dr. Gaurav Chandra, said, "We continue to make rapid strides with our Artificial Intelligence Platform. Our unique AI platform has been driving the Company's discoveries and drug development. Enzolytics has a robust Artificial Intelligence Platform for genomic surveillance and monitoring of viral epidemiology that is used to identify conserved targets for produced Monoclonal Antibodies. The Company's Artificial Intelligence platform has also been used to build AI-generated 3D Models of all the conserved targets. The analysis of these conserved sequences revealed that all epitopes identified by the Company are linear, accessible by antibodies, and unaffected by mutations. Therefore, Monoclonal Antibodies produced against these targets will expectedly be universal, durable, broadly neutralizing, and unaffected by virus mutation."Monkeypox is a zoonotic orthopoxvirus that incidentally causes disease in humans similar to smallpox, although with notably lower mortality. Two types (West African-usually, seen in Nigeria, and Central African-usually, seen in the Congo River Basin) have a higher case fatality rate, approx. 10.6%. Between 1 January to 15 June 2022, a cumulative total of 2103 laboratory-confirmed cases, one probable case, and one death have been reported to WHO from 42 countries.The public health risk could become high if this virus exploits the opportunity to establish itself as a human pathogen and spreads to groups at higher risk of severe diseases such as young children and immunosuppressed persons. According to a WHO risk assessment issued 06/12/22, "immediate action from countries is required to control further spread among groups at risk, prevent spread to the general population and avert the establishment of Monkeypox as a clinical conditi...